| Gender Preference | None |
| Age Group | 6 - 99 years |
| Research Start Date | February 18, 2013 |
| Research End Date | August 22, 2014 |
| Principal Investigator | Richard Ahrens, MD |
| Description | The purpose of this study is to learn more about the safety and effects of Kalyedco in subjects with CF who are 6 years old and older, with at least one copy of the R117H-CFTR mutation. We will also look at how Kalyedco may affect your body and how your body breaks down and eliminates ivacaftor. |
| Contact Info | Mary Teresi PharmD mary-teresi@uiowa.edu |
| Keywords | span itemProp='description'>Cystic Fibrosis ; R117H genotype ; |